EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cell-Type-Resolved Mendelian Randomization, Colocalization and Druggability of Asthma Using Single-Cell Immune eQTL.

Piao Zhang, Dongyi Luo, Qian Liu

Genes · 15.11.2026 · 17 (11) · 1434

DOI: 10.3390/genes17111434 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Genes, online erschienen am 15.11.2026. Verfasst von Piao Zhang und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Genome-wide association studies (GWAS) have identified over 212 asthma susceptibility loci, yet the effector genes and the immune cell subsets remain largely unresolved, because conventional prioritization relies on bulk-tissue expression quantitative trait loci (eQTL) that cannot resolve cellular heterogeneity. We aimed to build a cell-type-resolved map of candidate causal genes and prioritize druggable asthma targets.

Methods

We integrated single-cell cis-eQTL across 20 peripheral-blood immune subsets from OneK1K with a European-ancestry asthma GWAS meta-analysis from the Global Biobank Meta-analysis Initiative (121,940 cases, 1,254,131 controls), using summary-data-based Mendelian randomization (SMR) with heterogeneity in dependent instrument (HEIDI) filtering followed by Bayesian colocalization, and annotated dual-evidence genes for tractability with the Open Targets Platform.

Results

Across 12,754 gene–cell-subset tests, 437 associations were significant (false discovery rate < 0.05, HEIDI pass), implicating 202 genes. Colocalization supported 102 associations across 46 dual-evidence genes. At 17q21, ORMDL3 colocalized in B cells and GSDMB in natural killer, CD8+ effector-memory T and naive B cells. The IL18R1 signal (2q12) did not colocalize, consistent with linkage disequilibrium. In independent eQTL data, 18 of the 46 replicated in at least one pre-specified endpoint, including 10 in whole blood against one of 202 control genes, while the other 28 remain candidates. Twenty-three of the 46 carried tractability evidence, three at a clinical stage.

Conclusions

Single-cell eQTL-based Mendelian randomization refines understanding of asthma genetic architecture and delivers a cell-type-anchored shortlist of candidate therapeutic targets. This two-pillar, cell-type-resolved framework yields testable mechanistic insights and supports translational development of precision therapeutic strategies for asthma.

Zitieren

APA

Zhang, P., Luo, D., & Liu, Q. (2026). Cell-Type-Resolved Mendelian Randomization, Colocalization and Druggability of Asthma Using Single-Cell Immune eQTL. Genes, 17(11), 1434. https://doi.org/10.3390/genes17111434

Vancouver

Zhang P, Luo D, Liu Q. Cell-Type-Resolved Mendelian Randomization, Colocalization and Druggability of Asthma Using Single-Cell Immune eQTL. Genes. 2026;17(11):1434. doi:10.3390/genes17111434

BibTeX
@article{Zhang2026,
  author = {Zhang, Piao and Luo, Dongyi and Liu, Qian},
  title = {Cell-Type-Resolved Mendelian Randomization, Colocalization and Druggability of Asthma Using Single-Cell Immune eQTL},
  journal = {Genes},
  year = {2026},
  volume = {17},
  number = {11},
  pages = {1434},
  doi = {10.3390/genes17111434}
}
Kostenlos starten →